FIGURE 1.
CircNFIB is decreased in cardiac fibrosis. (A) CircNFIB is decreased in ventricle samples from 21 days post-myocardial infarction mice (n = 5:6). (B) circNFIB is decreased in primary adult cardiac fibroblasts treated by TGF-β (n = 5:6). (C) Results of sequencing of divergent PCR products generated from circNFIB confirmed the head-to-tail junction point. (D) The transfection efficacy of circNFIB plasmid is confirmed by qRT-PCR (n = 6). (E) The transfection efficacy of circNFIB siRNA is confirmed by qRT-PCR (n = 4). *p < 0.05, ∗∗p < 0.01 versus controls.